ShareProphets

The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares


Join ShareProphets at less than 2p per article

> All the big AIM fraud exposés

> 300 articles and podcasts a month

> Hot share tips

> Original investigations by our experienced team

> No ads, no click-bait, no auto-play videos

Find out more

Creightons – trading update & R&D recovery, upcoming results to highlight value?

By Tom Winnifrith & Steve Moore | Tuesday 21 May 2019


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Developer, manufacturer and marketer of toiletries and fragrances, Creightons (CRL) has updated including “sales in the second half of the year to 31 March 2019 are likely to be broadly similar to those for the first half, but there will be a one-off benefit from the recovery of R&D expenditure”

You have reached premium content

You must be a paid subscriber to see this page.

Already a subscriber? Click here to sign in



This area of the ShareProphets.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ShareProphets.com. ShareProphets.com does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ShareProphets.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ShareProphets.com and is not intended to be relied upon by users in making (or refraining from making) any investment decisions.


Site by Everywhen